Filgrastim Biosimilars Market Outlook Through 2030: Understanding The Growth Opportunity
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Filgrastim Biosimilars Market Revenue Growth On Track For A 11.9% CAGR Through 2030
The filgrastim biosimilars market size has experienced rapid growth in recent years. It is anticipated to increase from $1.19 billion in 2025 to $1.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. The expansion witnessed in the historic period can be linked to the high cost of originator filgrastim, the rising prevalence of cancer and blood disorders, constrained access to biologics in developing regions, advancing hospital infrastructure, and swift approvals of biosimilars by regulatory authorities.
The filgrastim biosimilars market size is projected to experience swift expansion over the coming years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by several factors, including the introduction of advanced filgrastim biosimilars, broader contract manufacturing collaborations, increased application in chronic and autoimmune conditions, augmented government backing and reimbursement frameworks, and the evolution of patient-focused distribution and delivery strategies. Key developments expected during this period encompass the growing integration of filgrastim biosimilars in oncology and blood disorder therapies, the expansion of contract manufacturing organizations dedicated to biosimilar production, a greater reliance on internal vertically integrated manufacturing sites, a developing preference for hospital and retail pharmacy distribution channels, and a concentrated effort on affordable biologics and market accessibility in developing regions.
Get A Free Sample Report With In-Depth Market Insights:
Filgrastim Biosimilars Market Growth Factors: What’s Supporting Expansion?
An anticipated increase in cancer cases is projected to fuel the expansion of the filgrastim biosimilars market in the future. Cancer encompasses various illnesses characterized by the unchecked proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that impair regular cellular control. This surge in cancer occurrence is partially attributable to an aging populace, given that extended lifespans increase the probability of genetic mutations contributing to cancer development. Filgrastim biosimilars assist individuals with cancer by stimulating the production of white blood cells, thereby mitigating the danger of neutropenia induced by chemotherapy and facilitating safer, uninterrupted cancer therapy. For example, the National Health Service (NHS), a government health organization in the UK, reported in October 2025 that 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the escalating rate of cancer incidence is propelling the filgrastim biosimilars market.
Filgrastim Biosimilars Market Segmentation And Category Overview
The filgrastim biosimilars market covered in this report is segmented –
1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services
Filgrastim Biosimilars Market Industry Trends: What’s Reshaping Demand?
Leading companies in the filgrastim biosimilar market are advancing product development by utilizing sophisticated technologies, such as recombinant DNA technology, to manufacture biosimilars. Recombinant DNA technology is a process involving the creation of hybrid or chimeric DNA by inserting an external sequence into an organism’s DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FYLNETRA (pegfilgrastim-pbbk) in the United States. This product, a biosimilar to Amgen’s NEULASTA, is indicated for both the treatment and prevention of febrile neutropenia. It works by encouraging the growth and specialization of neutrophils derived from dedicated precursor cells, triggering their maturation, and improving the viability and efficiency of fully developed neutrophils, which leads to dosage-dependent increases in neutrophil counts. The introduction of Fylnetra contributes to the next generation of affordable medications and expands access for patients, healthcare providers, and payors.
Filgrastim Biosimilars Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.
View The Full Filgrastim Biosimilars Market Report:
Filgrastim Biosimilars Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
